{"id":1023077,"date":"2026-11-21T18:17:01","date_gmt":"2026-11-21T23:17:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/"},"modified":"2026-11-21T18:17:01","modified_gmt":"2026-11-21T23:17:01","slug":"nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/","title":{"rendered":"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law"},"content":{"rendered":"<p>        <!--.bwuline { text-decoration: underline }\n.bwalignl { text-align: left }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law<\/p>\n<p>LOS ANGELES&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fschallfirm.com%2F&amp;esheet=54645063&amp;newsitemid=20261121449424&amp;lan=en-US&amp;anchor=Schall%2C+Brown+%26+Schwartz&amp;index=1&amp;md5=f3db4581beae4f489510c91e3b443fee\">Schall, Brown &amp; Schwartz<\/a> LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nurix Therapeutics, Inc. (\u201cNurix\u201d or \u201cthe Company\u201d) (NASDAQ: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FNRIX&amp;esheet=54645063&amp;newsitemid=20261121449424&amp;lan=en-US&amp;anchor=NRIX&amp;index=2&amp;md5=bacc954a2adcd0e26d9d1f128114315b\">NRIX<\/a>) for violations of the securities laws.<\/p>\n<p><b>INVESTIGATION DETAILS: <\/b>The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Nurix revealed on November 3, 2026, that Sanofi decided to discontinue its Phase 1 trial of SAR448272, the Company\u2019s investigational drug intended to treat inflammatory diseases, as well as to terminate development of the drug altogether. Based on this news, shares of Nurix fell by more than 38.2% on the next day.<\/p>\n<p>If you are a shareholder who suffered a loss, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fschallfirm.com%2Fcases%2Fnurix-therapeutics-inc%2F&amp;esheet=54645063&amp;newsitemid=20261121449424&amp;lan=en-US&amp;anchor=click+here+to+participate&amp;index=3&amp;md5=52064930ab35f52aa9480b63dea45db1\">click here to participate<\/a>.<\/p>\n<p>We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown &amp; Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fpr.report%2FmIwBkOrU&amp;esheet=54645063&amp;newsitemid=20261121449424&amp;lan=en-US&amp;anchor=www.schallfirm.com&amp;index=4&amp;md5=397e4fe5fd3c449da532e36f6856a5a2\"><span class=\"bwuline\">www.schallfirm.com<\/span><\/a>, or by email at <a rel=\"nofollow\" href=\"mailto:david@schallfirm.com\">david@schallfirm.com<\/a>.<\/p>\n<p><strong>WHY SBS?<\/strong> Schall, Brown &amp; Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.<\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261121449424\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261121449424\/en\/<\/a><\/span><\/p>\n<p class=\"bwalignl\">Schall, Brown &amp; Schwartz LLP<br \/>Brian Schall, Esq.,<br \/>Andrew Brown, Esq.,<br \/>David Schwartz, Esq.,<br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.schallfirm.com&amp;esheet=54645063&amp;newsitemid=20261121449424&amp;lan=en-US&amp;anchor=www.schallfirm.com&amp;index=5&amp;md5=8fee39e02f56f0f99784d69f29c11d88\">www.schallfirm.com<\/a><br \/>Office: 310-301-3335<br \/><a rel=\"nofollow\" href=\"mailto:info@schallfirm.com\"><span class=\"bwuline\">info@schallfirm.com<\/span><\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261121449424\/en\/2860466\/3\/SBSAttorney-LOGO-DI-1A-Final.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES&#8211;(BUSINESS WIRE)&#8211;Schall, Brown &amp; Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nurix Therapeutics, Inc. (\u201cNurix\u201d or \u201cthe Company\u201d) (NASDAQ: NRIX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Nurix revealed on November 3, 2026, that Sanofi decided to discontinue its Phase 1 trial of SAR448272, the Company\u2019s investigational drug intended to treat inflammatory diseases, as well as to terminate development of the drug altogether. Based on this news, shares of Nurix fell &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1023077","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES&#8211;(BUSINESS WIRE)&#8211;Schall, Brown &amp; Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nurix Therapeutics, Inc. (\u201cNurix\u201d or \u201cthe Company\u201d) (NASDAQ: NRIX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Nurix revealed on November 3, 2026, that Sanofi decided to discontinue its Phase 1 trial of SAR448272, the Company\u2019s investigational drug intended to treat inflammatory diseases, as well as to terminate development of the drug altogether. Based on this news, shares of Nurix fell &hellip; Continue reading &quot;NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-21T23:17:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law\",\"datePublished\":\"2026-11-21T23:17:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\"},\"wordCount\":331,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\",\"name\":\"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-11-21T23:17:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/","og_locale":"en_US","og_type":"article","og_title":"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk","og_description":"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law LOS ANGELES&#8211;(BUSINESS WIRE)&#8211;Schall, Brown &amp; Schwartz LLP (\u201cSBS\u201d), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nurix Therapeutics, Inc. (\u201cNurix\u201d or \u201cthe Company\u201d) (NASDAQ: NRIX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Nurix revealed on November 3, 2026, that Sanofi decided to discontinue its Phase 1 trial of SAR448272, the Company\u2019s investigational drug intended to treat inflammatory diseases, as well as to terminate development of the drug altogether. Based on this news, shares of Nurix fell &hellip; Continue reading \"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-21T23:17:01+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law","datePublished":"2026-11-21T23:17:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/"},"wordCount":331,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/","name":"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-11-21T23:17:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261121449424r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nrix-investors-have-opportunity-to-join-nurix-therapeutics-inc-fraud-investigation-with-sbs-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1023077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1023077"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1023077\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1023077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1023077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1023077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}